Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics
- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases
- Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform
Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces it will present a poster containing key data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics, which is being held in Loutraki, Ancient Corinth, Greece, on June 11-16, 2024.
